title: Ranolazine refractory angina registry: 1-year results.
abstract: Patients with refractory angina (RA) have limited therapeutic options and significant limitations in their quality of life. Ranolazine is approved for patients with chronic stable angina but has not been studied in patients with RA. The Ranolazine Refractory Angina Registry was designed to evaluate the safety, tolerability, and effectiveness in RA patients. In a dedicated RA clinic using an extensive prospective database, 100 patients were enrolled. Angina class, medications, major adverse cardiac events including death, myocardial infarction, and revascularization were obtained at 1, 6, and 12 months. Overall 43% of patients had a ≥2 class improvement in angina. At 1 year, 57% patients remained on ranolazine (91.2%; 500 mg BID), including 58% with a ≥2 class improvement in angina. Reasons for discontinuation included: side effects (n = 16), major adverse cardiac events (n = 10), cost (n = 5), ineffective (n = 6), cost and ineffective (n = 3), and unknown (n = 3). In conclusion, ranolazine is an effective antianginal therapy in patients with RA; still at 1 year only 57% of patients remained on ranolazine because of side effects, suboptimal effectiveness, cost, or progression of disease.
authors: From the *Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN; †University at Buffalo, Buffalo, NY; and ‡Cedars-Sinai Heart Institute, Los Angeles, CA.
authors: Noel M
authors: NM
authors: Bennett
authors: Vijay
authors: V
authors: Iyer
authors: Theresa L
authors: TL
authors: Arndt
authors: Ross F
authors: RF
authors: Garberich
authors: Jay H
authors: JH
authors: Traverse
authors: Randall K
authors: RK
authors: Johnson
authors: Anil K
authors: AK
authors: Poulose
authors: Annie
authors: A
authors: Lips
authors: Jill M
authors: JM
authors: Morgan
authors: Timothy D
authors: TD
authors: Henry
mesh_terms: D000083:Acetanilides / Q000008:administration & dosage / Q000009:adverse effects; D000368:Aged; D000787:Angina Pectoris / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D003627:Data Interpretation, Statistical; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D062072:Patient Acuity; D010352:Patient Dropouts; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects; D011358:Product Surveillance, Postmarketing / Q000379:methods / Q000706:statistics & numerical data; D000069458:Ranolazine; D012042:Registries / Q000706:statistics & numerical data; D016896:Treatment Outcome; D014481:United States
chemical_list: D000083:Acetanilides; D004791:Enzyme Inhibitors; D010879:Piperazines; D000069458:Ranolazine